These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20623636)

  • 1. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.
    Lin E; Wang Q; Swenson S; Jadvar H; Groshen S; Ye W; Markland FS; Pinski J
    Prostate; 2010 Sep; 70(12):1359-70. PubMed ID: 20623636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
    Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH
    Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity.
    Swenson S; Costa F; Ernst W; Fujii G; Markland FS
    Pathophysiol Haemost Thromb; 2005; 34(4-5):169-76. PubMed ID: 16707922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
    Brubaker KD; Brown LG; Vessella RL; Corey E
    BMC Cancer; 2006 Jan; 6():15. PubMed ID: 16417633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo.
    Tian J; Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):230-6. PubMed ID: 20615620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of tumor formation by snake venom disintegrin.
    Yang RS; Tang CH; Chuang WJ; Huang TH; Peng HC; Huang TF; Fu WM
    Toxicon; 2005 Apr; 45(5):661-9. PubMed ID: 15777962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
    Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
    Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
    Wu JD; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Plymate SR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6153-60. PubMed ID: 17062692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
    Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET
    Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
    Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
    J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model.
    Markland FS; Shieh K; Zhou Q; Golubkov V; Sherwin RP; Richters V; Sposto R
    Haemostasis; 2001; 31(3-6):183-91. PubMed ID: 11910184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA
    Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.